FAQ

QVA149

 

Topic mentions per year

Topic mentions per year

2010-2017
05101520102017

Related topics

Related topics

3 relations

Broader (3)

GlycopyrrolateIndansQuinolones

Related mentions per year

Related mentions per year

1954-2018
1960198020002020
QVA149
Quinolones
Glycopyrrolate
Indans

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD
BACKGROUND The current Global initiative for chronic Obstructive Lung Disease (GOLD) treatment strategy recommends the use of one… (More)
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
Is this relevant?
2014
2014
Effect of QVA149 on lung volumes and exercise tolerance in COPD patients: the BRIGHT study.
INTRODUCTION QVA149 is a novel, inhaled, once-daily dual bronchodilator containing a fixed-dose combination of the long-acting β2… (More)
Is this relevant?
2014
2014
Dual bronchodilation with QVA149 reduces patient-reported dyspnoea in COPD: the BLAZE study.
We evaluated the effect of QVA149, a dual bronchodilator combining indacaterol and glycopyrronium, on direct patient-reported… (More)
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
Is this relevant?
2014
2014
Pooled safety analysis of the fixed-dose combination of indacaterol and glycopyrronium (QVA149), its monocomponents, and tiotropium versus placebo in COPD patients.
BACKGROUND To further assess the safety profile of the fixed-dose combination of indacaterol and glycopyrronium (QVA149) and its… (More)
Is this relevant?
Highly Cited
2013
Highly Cited
2013
Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study
We investigated the efficacy and safety of dual bronchodilation with QVA149 versus its monocomponents indacaterol and… (More)
Is this relevant?
Highly Cited
2013
Highly Cited
2013
Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group…
BACKGROUND We evaluated the effect of dual, longacting inhaled bronchodilator treatment on exacerbations in patients with severe… (More)
Is this relevant?
Highly Cited
2013
Highly Cited
2013
Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel…
BACKGROUND QVA149 is an inhaled fixed-dose combination therapy under development for the treatment of chronic obstructive… (More)
Is this relevant?
2013
2013
Safety and efficacy of dual bronchodilation with QVA149 in COPD patients: the ENLIGHTEN study.
BACKGROUND QVA149 is an inhaled, once-daily fixed-dose dual bronchodilator combination of the long-acting β2-agonist indacaterol… (More)
  • figure 1
  • figure 2
  • table 1
  • table 3
  • table 2
Is this relevant?
2010
2010
QVA149 demonstrates superior bronchodilation compared with indacaterol or placebo in patients with chronic obstructive pulmonary disease.
BACKGROUND This randomised, double-blind, placebo controlled, four-period crossover study assessed the efficacy and safety of… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?
2010
2010
Cardiovascular safety of QVA149, a combination of Indacaterol and NVA237, in COPD patients.
This study assessed the cardiovascular safety of QVA149, an inhaled, once daily, bronchodilator combination containing two 24… (More)
  • table 1
  • figure 1
  • table 2
  • figure 2
  • table 3
Is this relevant?